

1 **Washington Vaccine Association**
2 **Board of Directors Meeting**
3 **November 2, 2023; 2:00-4:00 p.m. (PT)**
4

5 **I. Attendance.** This meeting was conducted virtually. Participating in all or part of the meeting were the following
6 individuals:

7		
8	<u>Directors</u>	22
9	John Dunn, MPH, MD, Kaiser Permanente, <i>Chair</i>	23 <u>Helms & Company, Inc.</u>
10	Beth Harvey, MD, South Sound Pediatrics, <i>Vice Chair</i>	24 Patrick Miller, MPH, WVA, Administrative Director
11	Ed Marcuse, MD, MPH, FPIDS, University of	25 Ashley Ithal, MPH, WVA, Program Support
12	Washington, <i>Secretary</i>	26 Leslie Walker, CPA, Mason+Rich, PA
13	John Sobeck, MBA, MD, Regence Blue Shield, <i>Treasurer</i>	27
14	Helen Chea, MD, Molina	28 <u>Others</u>
15	Kara Manley, United Healthcare	29 Janel Jorgenson, Washington Department of Health
16	Michele Roberts, Washington Department of Health	30 Katie Kolan, JD, Leonard & Kolan
17	Pamela Sheffield, MD, Aetna	31 Anne Redman, Esq., Perkins Coie
18		32 Jamilia Sherls-Jones, Washington Department of Health
19	<u>WVA</u>	33 Breeilyn Young, GSK
20	Julia Walter Zell, MA., Esq., Executive Director	34 Cameron Young, Leonard & Kolan
21	Cheri Cagle, Stakeholder Liaison	
22		

23
24
25
26
27
28
29
30
31
32
33
34
35
36 **II. Summary of Actions Taken and/or Recommended**
37

38 Actions Taken (votes adopted)

- 39 i. To approve the minutes of the June 15, 2023, Board Meeting
40 ii. To approve the minutes of the September 28, 2023, Board Meeting
41 iii. Vote to Reappoint Members (Chea and Murphy)
42 iv. Votes to Elect Officers / Committee Chairs
43 v. Vote to Ratify 2022-23 Audited Financial Statements
44 vi. Vote to add new vaccines to the Assessment Grid
45 vii. Vote to approve / publish 2022-23 Annual Report
46

47 **III. Minutes**
48

49 Welcome and Introductions

50 Dr. Dunn called the meeting to order at 2:02 p.m. Ms. Zell provided a notice of recording. Ms. Kolan and Mr.
51 Young with Leonard & Kolan introduced themselves to the group, noting that they will be assisting the WVA with
52 lobbying efforts to support the technical statutory fix..
53

54 Consent Calendar

55 Dr. Dunn asked for a motion to approve the minutes. Upon motion duly made and seconded, it was unanimously
56

57 **VOTED: To approve the minutes of the June 15, 2023, Board Meeting.**
58

59 Dr. Dunn asked for a motion to approve the minutes. Upon motion duly made and seconded, it was unanimously
60

61 **VOTED: To approve the minutes of the September 28, 2023, Board Meeting.**
62

63 Dr. Dunn asked for a motion to reappoint members. Upon motion duly made and seconded, it was unanimously
64

65 **VOTED: To reappoint members whose terms expire in 2023 (Dr. Chea and Mr. Murphy).**
66

67 Dr. Dunn asked for a motion to elect officers and committee chairs. Upon motion duly made and seconded, it was
68 unanimously
69

70 **VOTED: To Elect Officers / Committee Chairs with changes described at the meeting.**

71
72 **IV. Financial Updates**

73
74 Current Financials

75 Ms. Zell noted that in lieu of distributing the September ED/AD Report, Mr. Miller will review the key performance
76 indicators. Mr. Miller summarized the unaudited financials through September 30, 2023. Mr. Miller reported that cash
77 balances for the last nine months have ended the month with less than the beginning, as planned. In August and
78 September, the burn down accelerated as reserves were used to fund COVID-19 vaccines and the nirsevimab
79 monoclonal antibody for RSV. For the year, the WVA has a \$4.3 million-dollar net positive variance. For
80 administrative expenses, the WVA is currently close to \$73,000 ahead of budget.

81
82 Finance Committee Update

83 Ms. Zell reported that the 2022-2023 audited financials were presented to the Finance Committee by the auditors. The
84 auditors stated that there was a clean audit. Ms. Zell stated that the audit went smoothly despite the new auditor team
85 members needing some education on the WVA's processes. Dr. Sobeck reiterated that the audit went smoothly. Ms.
86 Zell added that the WVA had a bond portfolio evaluation that confirmed the financial integrity of Morgan Stanley's
87 reports.

88
89 Dr. Dunn asked for a motion to ratify the 2022-2023 audited financial statements. Upon motion duly made and
90 seconded, it was unanimously

91
92 **VOTED: To ratify 2022-23 Audited Financial Statements.**

93
94 **V. ED/AD Updates**

95
96 Cash Reserves/Future Assessment Grid

97 Mr. Miller noted that the organization's reserve levels have historically been set to account for three months of
98 vaccine expenditures plus influenza. In April 2023, he last reserve goal was set so that cash at the end of 2025 and
99 2026 fiscal years would be \$30M and \$32M, respectively. Given the addition of COVID-19 vaccines, the
100 nirsevimab monoclonal antibody, and anticipated costly off-cycle vaccines, Mr. Miller proposed that the reserve
101 target be closer to \$45M. Mr. Miller shared data demonstrating how new products entering the market are priced
102 significantly higher than historically seen so accounting for that in future projections is important. He concluded by
103 stating that the WA Department of Health (DOH) estimates for COVID-19 vaccines and the nirsevimab monoclonal
104 antibody are wide ranging in terms of uptake, which will have a large impact on the final reserve targets to be
105 chosen in April 2024.

106
107 Off Cycle Vaccine Additions

108 Ms. Zell reported that the Operations Committee voted to approve adding Abrysvo™, Penbraya™, and Jynneos® to
109 the Assessment Grid when made available through the CVP, and that additional Board approval is required. Ms. Zell
110 reminded the group that provisional approval of these vaccines is to satisfy the 60-day notice requirement to payers.

111
112 Dr. Dunn asked for a motion to approve the new vaccines. Upon motion duly made and seconded, it was unanimously

113
114 **VOTED: To add new vaccines to the Assessment Grid.**

115
116 COVID Roll-out

117 Mr. Miller reported that just under 7,000 DBAs have been received to date. The WVA has sent two communications
118 to providers, and the WA DOH has also sent out multiple communications. Mr. Miller stated that payer compliance
119 reports have been run to identify issues with incorrect grid amounts or denials. Communications to payers with
120 identified issues are ongoing.

121
122 RSV/Statutory Update/In-Patient Hospital Assessments

123 Ms. Zell reported that all payers have signed and returned their respective nirsevimab agreements to authorize the
124 use of reserves until next year. She thanks all the Board members for their help in getting those agreements signed.

126 Ms. Kolan provided a statutory update and thanked Ms. Roberts and the WA DOH team for collaborating with her
127 team on the coalition building planning. Ms. Kolan noted that the upcoming legislative session begins on January 8th
128 and is 60 days in length. There will be one group focused on statutory update communication and another focused
129 on legislator lobbying.

130

131 Ms. Zell noted that the group is counting on the statutory update to pass and preparation will begin for determining
132 how inpatient hospital assessments will occur. She reported that a multi-stakeholder taskforce will be convened at
133 the end of the month to discuss how the inpatient billing will work.

134

135 Annual Report

136 Ms. Zell provided an overview of the 2022-2023 Annual Report. Dr. Dunn asked for a motion to approve the report.
137 Upon motion duly made and seconded, it was unanimously

138

139 **VOTED: To approve and publish the 2022-23 Annual Report.**

140

141 **VI. WA DOH Updates**

142

143 Ms. Roberts thanked the providers and the WVA staff for working with the WA DOH on recently rollouts,
144 especially COVID-19 vaccines and the nirsevimab monoclonal antibody. She reported that the COVID-19 vaccine
145 supply has started to stabilize despite initial access issues.

146

147 Ms. Sherls-Jones reported that COVID-19 hospitalizations and emergency room visits remain low but that rates are
148 expected to rise. This is the first time that immunizations are available for all fall viruses. Nirsevimab ordering has
149 temporarily halted due to supply chain issues and the WA DOH have communicated this to providers. Ms. Sherls-
150 Jones will notify Ms. Zell when ordering has begun again. Ms. Sherls-Jones reported that the WA DOH has reached
151 out to the CDC directly about future doses being made available as well as the hardships that are being experienced.

152

153 **VII. Public Comments**

154

155 No public comments.

156

157 **VIII. Executive Session - Confidential.** On file with general counsel.

158

159 **IX. Closing**

160

161 With no further business before the Board, Dr. Dunn closed the meeting at 4:00 p.m.